Phase Ib Randomised, Placebo-controlled, Double-blind, Multicentre Study to Assess the Effects and Safety of AZD5462 on top of Dapagliflozin in Participants with Heart Failure and Moderate Renal Impairment

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513142-11-00

Acronym

D9090C00007

Enrollment

Registered

2024-09-10

Start date

2024-09-27

Completion date

2025-05-29

Last updated

2025-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure, Moderate Renal Impairment

None listed

Sex/Gender

All

Age

18 Years to No maximum

Bulgaria, Sweden

None listed

Source: EU CTIS · Data processed: Feb 4, 2026